The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relativesof Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinicalsignificance of screening for monoclonal gammopathy (M-protein) in first-degree relativesof patients with multiple myeloma in China population, and establish a prospective cohortof individuals with monoclonal gammopathy of undetermined significance (MGUS), aprecursor conditions to multiple myeloma. We will study these patients as a means toidentify risk factors for progression to symptomatic multiple myeloma.
The CHAPERONE study aims to assess the clinical significance of screening for monoclonal
gammopathy in first-degree relatives of patients with multiple myeloma in China.
The main objectives it aims to answer are:
- Main research objectives: To study the prevalence of MGUS, the time of disease
progression, and its influencing factors in first-degree relatives of multiple
myeloma patients in China.
- Secondary study objective: To explore the clinical/genomic/epigenetic features,
survival, and quality of life of MGUS patients in first-degree relatives of multiple
myeloma patients in China.
All participants will receive M-protein screening by serum electrophoresis. Individuals
with detected M-protein will undergo further diagnostic tests, and patients with MGUS
will be carefully assessed and followed up.
Diagnostic Test: Sample of Blood
All participants will receive M-protein screening by serum electrophoresis. Individuals
with detected M-protein will undergo further diagnostic tests to determine their accurate
diagnosis. Patients with monoclonal gammopathy of undetermined significance (MGUS) would
be carefully assessed and followed up.
Inclusion Criteria:
1. Male or female over the age of 18;
2. First-degree relatives (including parents, children, and biological siblings) have
multiple myeloma diagnosed by the International Myeloma Working Group (IMWG) Myeloma
Diagnostic Criteria;
3. Understand the purpose and procedure of this trial and voluntarily participate in
this screening study;
4. Participants should be willing and able to follow the study follow-up plan and other
protocol requirements.
Exclusion Criteria:
Patients with a known diagnosis of plasma cell diseases, such as MGUS, smoldering myeloma
(SMM), or multiple myeloma
Zhongshan Hospital，Fudan University
Shanghai, Shanghai, China
Investigator: Peng Liu, Ph.D
Contact: +862164041990
liu.peng@zs-hospital.sh.cn
Peng Liu, PhD, MD
+8621-64041990 - 2925
liu.peng@zs-hospital.sh.cn
Jing Li, MD
+8621-64041990 - 2025
li.jing6@zs-hospital.sh.cn
Peng Liu, PhD, MD, Principal Investigator
Fudan University